The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid. Bullous pemphigoid ...

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

Bulla has lifted its farmgate milk price as global butter prices soar, priming the market for higher prices in 2025-26. Butterfat is critical to Bulla’s production of ice-cream and cream lines ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food and ...

Languages used at home data is based on place of usual residence Households where a non-English language is used is based on place of enumeration Note 1: Calculated percentages represent a proportion ...